Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 Years experience

International Journal of Urology

Volumn 11, Issue 8, 2004, Pages 592-596

  Saito, Motoaki ^a,b   Watanabe, Takeshi ^a   Tabuchi, Fumie ^a   Otsubo, Kenji ^a   Satoh, Keisuke ^a   Miyagawa, Ikuo ^a  

^a TOTTORI UNIVERSITY HOSPITAL   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Hydroxypropylcellulose; Intravesical oxybutynin chloride; Overactive bladder; Side effect

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; HYDROXYPROPYLCELLULOSE; OXYBUTYNIN; PROPIVERINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLADDER CAPACITY; CLINICAL ARTICLE; CONSTIPATION; CYSTITIS; CYSTOMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; ILEUS; JAPAN; MALE; MEASUREMENT; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT OUTCOME; URETER CANCER; URODYNAMICS; XEROSTOMIA;

ADMINISTRATION, INTRAVESICAL; ADOLESCENT; AGED; CELLULOSE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; PATIENT SATISFACTION; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; URODYNAMICS;

EID: 4344696662     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00871.x     Document Type: Article

References (11)

1. Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. J. Urol. 1992; 148: 595-7.
2. Mizunaga M, Kaneko S, Miyata M et al. New intravesical oxybutynin hydrochloride used for the treatment of neurogenic bladder dysfunction. Neurourol. Urodyn. 1996; 15: 306-7.
3. Buyse G, Waldeck K, Verpoorten C, Bjork H, Casaer P, Andersson K-E. Intravesical oxybutynin for neurogenic bladder dysfunction: Less systematic side effects due to reduced first pass metabolism. J. Urol. 1998; 160: 892-6.
4. Madersbacher H, Knoll M. Intravesical application of oxybutynin: Mode of action in controlling detrusor hyperreflexia. Eur. Urol. 1995; 28: 340-4.
5. Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J. Urol. 1991; 146: 532-4.
6. Saito M, Tabuchi F, Otsubo K, Miyagawa I. Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol. Urodyn. 2000; 19: 683-8.
7. Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J. Urol. 1988; 141: 1350-2.
8. Weese DL, Roskamp DA, Leach GE, Zimmern PE. Intravesical oxybutynin chloride: Experience with 42 patients. Urology 1993; 41: 527-30.
9. Kasabin NG, Vlachiotis JD, Lais A et al. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J. Urol. 1994; 151: 944-5.
10. Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complication of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J. Urol. 1997; 157: 638-40.
11. Amark P, Bussman G, Eksborg S. Follow-up of long time treatment with intravesical oxybutynin for neurogenic bladder children. Eur. Urol. 1998; 34: 148-53.